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摘 要 
摘 要 
慢性肾脏病（Chronic Kidney Disease，CKD）普遍存在维生素 D水平降低情
况，并认为维生素 D 的降低与继发性甲状旁腺功能亢进（ secondary 
Hyperparathyroidism sHPT）及降低骨密度相关。骨化三醇（Calcitriol）作为一种
活性维生素 D在慢性肾脏病中广泛应用，其能够有效降低 iPTH水平。近年来人
们发现 Calcitriol在抗纤维化的过程中起重要用，本研究主要就 Calcitriol能否通
过上调抗衰老蛋白 Klotho 进而延缓肾损伤展开讨论，为证明这一假说建立了大
鼠肾衰模型，全身性给予实验组大鼠 Calcitriol 后检测大鼠血清及组织中 Klotho
蛋白与肾脏纤维化之间的关系，尝试解释骨化三醇抑制肾脏纤维化的机制，为骨
化三醇的进一步利用提供参考。 
试验方法： 
1）动物实验：建立肾衰试验动物模型，将大鼠随机分为假手术组（Sham组，
n=11），5/6肾切除大鼠结合高磷饮食组（Nx-Hp，n=11）及 5/6肾切除结合高磷
饮食及药物干预组（Nx-Hp+Cal，n=10）。分别于术后第 4、12周检测行眼底静
脉采血，并在实验结束时处死所有实验大鼠，取肾脏组织，染色观察肾脏组织的
病理形态和胶原纤维沉积情况，并行病理积分。应用 qRT-PCR 检测大鼠肾组织
KlothomRNA的表达、Elisa检测大鼠血清 Klotho、FGF-23、TGF-β1，用免疫组
化及Western blot技术分别观察大鼠肾组织 Klotho蛋白的表达情况，并分别对比
分析三组大鼠 Klotho表达强度的差异。 
2）细胞试验：体外培养大鼠肾小管上皮细胞(NRK-52E)，分为对照组、TGF-
β1处理组、药物干预组及Klotho基因敲除组。TGF-β1因子（最终浓度为 2ng/ml）
刺激大鼠肾小管上皮细胞，观察 Calcitrol对 TGF-β1刺激的大鼠肾小管上皮细胞
的影响，用 qRT-PCR和Western blot检测细胞 Klotho和 α-SMAmRNA及蛋白的
的变化。 
实验结果： 
（一）动物学实验： 
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1）用 HE及Masson染色方法观察肾脏组织的病理变化情况，手术对照组大
鼠肾脏组织基本正常，Nx-Hp 组肾脏局灶性肾小球硬化，肾小管上皮细胞变性、
萎缩甚至坏死明显，肾间质纤维化明显伴大量炎症细胞浸润，骨化三醇干预组肾
小球及肾小管的病变程度明显轻于试验组。 
2) 各 Nx组大鼠血肌酐和 iPTH水平明显升高，随造模时间的延长血肌酐及
iPTH呈逐渐升高趋势，12W时 Calcitriol干预组能明显降低血清 iPTH（P<0.05）。 
3）分别比较了各组大鼠血清 Klotho、FGF-23、TGF-β1水平，Nx-Hp组血清
中 Klotho下降，血清 FGF-23、TGF-β1因子呈上升趋势，并发现血清活性维生
素 D的应用可部分上调血清 Kotho水平，在 4W时这种现象最明显（P<0.05）。
相关性分析发现 s-Klotho与 TGF-β在 4W时存在明显相关性（R=0.47，P=0.02）。 
4）分别比较了各组大鼠相比肾脏组织中 Klotho、E-cadherin、TGFβ1 及 α-
SMA 等指标，结果表明 Nx-Hp 组大鼠肾组织 Klotho 降低最明显（P<0.05），
Calcitriol可部分上调抗衰老蛋白 Klotho的表达，部分抑制肾小管上皮-间质转分
化（EMT）过程。 
（二）细胞型实验： 
1）探究 TGF-β1干预对肾小管上皮细胞（NRK-52E）对细胞 Klotho表达的
影响，发现在 Klotho 表达降低的同时伴有 EMT 过程。通过对 Klotho 的上调
Calcitriol部分阻断 EMT过程。 
2）抑制肾小管上皮细胞 Klotho的表达，肾小管上皮细胞中α-SMA等纤维
化因子明显升高，同时 Calcitriol 抗纤维化能力显著减弱，降低 Calcitriol 抑制
TGFβ1的能力。 
实验结论：以上研究数据表明，Calcitriol可部分延缓肾脏纤维化，这一作用
可能是通过部分上调肾组织中 Klotho 表达并抑制肾小管上皮-间质转化（EMT）
实现的，因此为骨化三醇的临床应用和其肾保护机制提供了有力证据。 
关键词：骨化三醇；sHPT； Klotho；肾脏纤维化。
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Abstract 
Abstract 
Chronic Kidney Disease (CKD) patients generally have lower vitamin D levels. It 
is believed that the decrease of active vitamin D is associated with the secondary 
hyperparathyroidism and decreased bone mineral density. As a kind of active vitamin 
D, calcitriol is widely used in chronic kidney disease, which can delay the process of 
sHPT and renal fibrosis. However, the mechanism of calcitriol is still unclear. In this 
study, we discussed whether the calcitriol can inhibit renal injury by up regulating the 
anti-aging protein Klotho. In order to prove this hypothesis, we established rat renal 
failure model, to observed the relationship between renal fibrosis and the level of 
Klotho protein in serum and tissues of rats after administration of vitamin D. In this 
study, we explained the potential mechanism of calcitriol in inhibiting renal fibrosis, 
and provided a reference for the further utilization of calcitriol. 
（1）Animal experiment: 
To establish animal model of renal failure ，all 5/6 nephrectomy rats were 
randomly divided into 5/6 nephrectomy combined with high phosphorus diet group (Nx 
- Hp, n = 11) and 5/6 nephrectomy combined with high phosphorus diet and drug 
intervention group (Nx - Hp + Cal, n = 10).Respectively at the 4th, 12th week detection 
line of eyeground vein blood and postoperative  at the end of the experiment to be put 
to death all the experimental rats, kidney tissue,observed the pathological morphology 
of kidney tissue and collagen deposition. Detect Klotho mRNA expression in the rat 
kidney by qRT-PCR, Elisa to detect serum-Klotho, FGF - 23, TGF - beta 1, using 
immunohistochemistry and western blot technique respectively to observe the Klotho 
protein expression in renal tissue in rat, and comparative analysis of three groups of rats 
Klotho expression intensity difference. 
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1)  By HE and Masson staining method observed the pathological change of 
kidney tissue, basic normal operation control group in the rat kidney tissue, in Nx - Hp 
group kidney focal glomerular sclerosis, renal tubular epithelial cells degeneration and 
atrophy and necrosis, renal interstitial fibrosis significantly with a large number of 
inflammatory cells infiltration. Calcitriol intervention group glomerular and renal 
tubular lesion was significantly lighter than experimental group. 
2) the Nx group rats serum creatinine and iPTH level increased significantly (P < 
0.05), serum creatinine and iPTH die along with the extension of time showed a trend 
of increase, at the same time of Calcitriol intervention group can significantly reduce 
serum iPTH (P < 0.05), and can significantly decrease the rat serum creatinine level (P 
< 0.05). 
3) respectively to compare the groups of rats serum Klotho, FGF - 23, TGF - beta 
1 level, Nx - Hp group Klotho decline in serum, serum FGF - 23, TGF - beta 1 factor is 
on the rise, and found that serum 1, 25 (OH) 2 d3 and serum TGF - beta 1 factor was 
significantly negative correlation, we speculated that by lowering the TGF - beta 1 
Calcitriol levels play a role. 
4) were compared between groups compared to the rat kidney tissue of Klotho, E 
cadherin, TGF beta and alpha 1 - SMA, such as index, the results show that the Nx - 
Hp group rats kidney Klotho most obvious reduction, Calcitriol has partial raised anti-
aging Klotho protein expression, partial inhibition of renal tubular epithelial - 
mesenchymal transdifferentiation (EMT) process.  
(2) cell type experiment: 
1) To explore the TGF - beta 1 intervention of renal tubular epithelial cells (NRK 
- 52 e), the influence of the expression of cell Klotho found in the process of Klotho 
expression reduced at the same time accompanied by EMT. Calcitriol part blocking 
EMT process by raising the Klotho. 
IV 
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2) Inhibiting the expression of Klotho in renal tubular epithelial cells, alpha SMA 
and fibrosis factor significantly increased at the same time, the ability of Calcitriol anti 
fibrosis function significantly weakened at the sametime. 
Experimental conclusion: these data show that Calcitriol has partial delay renal 
fibrosis and the effects may be mediated by some raised klotho expression in renal 
tissue and inhibiting renal tubular epithelial - (EMT) implementation of conversion of 
interstitial accordingly for the clinical application of Calcitriol and its renal protective 
mechanism provides strong evidence. 
Keywords: Calcitriol; sHPT； Klotho; Kidney Fibrosis.  
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第一章 前 言 
第一章 前 言 
1.1慢性肾脏病（Chronic Kidney Disease, CKD） 
CKD患病率逐年增高,已成为全球关注的重要公共卫生问题之一，常常起病
隐匿，部分患者一经发现即进入终末期，此外 CKD常合并贫血、骨代谢异常及
心血管并发症，严重影响患者的生活质量，增加患者的死亡风险。2012年，中国
首个 CKD多中心流行病学调查[1]显示我国 CKD总患病率为 10.8%，据此估计中
国有 1亿多的 CKD患者，其中仅有约 12.5%的知晓率，我国终末期肾病（ESRD）
患者约 100-200万例[2]，相对于各个阶段的 CKD患者中 ESRD仅约占 1%。随着
CKD流行病学研究的不断推进和发展，CKD的危险因素也逐渐为人所知，除吸
烟、性别、肥胖、高血压、糖尿病等代谢性疾病相关与 CKD相关外，年龄被视
为 CKD的独立危险因子[3 4]，老年人中肾脏结构和功能的改变不仅与老年性疾病
相关也是器官老化的结果，与年轻人相比老年人患高血压、糖尿病的概率升高，
高血压及糖尿病是继发慢性肾脏病的重要病因。1999年 J.R. NYENGAARD[5]等
对 37名不同年龄段的成年健康人肾组织做相关分析发现，年龄大于 75岁的老年
人，约 30%肾组织会因为硬化而失去功能。年龄相关的肾脏病可能与血管收缩功
能紊乱、激素水平、GSTM基因突变导致的氧化应激能力降低及端粒长度的改变
等相关[6-8]。 
1.2肾脏纤维化 
1.2.1 EMT的定义 
上皮-间质转化（epithelial to mesenchymal transition，EMT）是指有极性的上
皮细胞通过一系列变化失去细胞极性以及细胞间的紧密连接，转化为具有间质表
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